

POLCRO – EUCROF Meeting

19th May 2014 Warsaw

Dr. Stefano Marini, MD
EUCROF President European Contract Research Organization Federation
Medical Scientific Advisor to TFS Trial Form Support

Topics

EUCROF Members

Accomplishments

- Administrative
- Visibility
- Education
- Communication
- Internal / external / internal + external
- Working Groups

Outlook





EUCROF Members

- EUCROF is a non-profit organisation founded on 2005
- Member are legal entities registered in at least one European Country:
 - Associations of CROs, or
 - Private companies working in Clinical Research Services



National Association	Country	No. CROs
1. ACRO-CZ	Czech Republic	18
2. ACRON	The Netherlands	40
3. AECIC	Spain	30
4. AFCROS	France	48
5. AICRO	Italy	13
6. ASCRO	Sweden	7
7. BeCRO	Belgium	29
8. BVMA	Germany	39
9. CCRA	United Kingdom	36
10.HACRO	Greece	10
11.SAKDER	Turkey	26


Local CROs

- 1. Portugal
- 2. Poland
- 3. Ireland
- 4. Denmark
- 5. Switzerland
- 6. Ukraine

TOTAL: 293 Companies, 17 Countries, over 16.000 employees



EUCROF Members Geographic Presence May - 2014





EUCROF Members Potential Full Members to Come

Poland:

• Ireland:

the Polish
Association has been founded in Q3 2012

the Irish
Association to be founded

soon

POLCRO

CRPI




Objectives


- Promote the quality of clinical research;
- Promote outsourcing to CROs attitude by improving knowledge, competence/expertise and skills of professionals within CROs in Europe;
- Represent and support CROs towards Regulatory Bodies, pharmaceutical, biotech, medical device and other healthcare related industry as well as medical, patients and affiliated research community, within the field of clinical research;
- Exchange relevant information and networking between Members;
- Extend CRO representation to all European territory.

EUCROF is a non-profit organisation.




















Accomplishments: Administrative

- SOPs made effective on 15 March 2013
 - Quality Statement
 - Master SOP
 - Establishment, Operation and Termination of EUCROF Working Groups
 - EUCROF Communication and Handling of Presentations and Other Documents
 - EUCROF Publications and Abstracts
- SOP Index
- Glossary



Accomplishments: Administrative

Finance





- Tax declaration generated for former years
- Significant growth of bank movements



Accomplishments: Visibility

EUCROF Conference, Paris:
 02-04 February 2015

Late Phase Research/Real-World Data, Dublin:
 22-23 May 2014

- DIA Europe, Amsterdam:
 ✓ EUCROF General Assembly 04 06 March 2013
- 3rd Conference of Clinical Research, Paris:
 31 January 2014



Accomplishments: Visibility

- EUCROF / RIPPS / EMA Conference:
 18 April 2013
 Methodological Approaches to overcome the challenges of Drug Evaluation in Children
- EUCROF Conference in Brussels: 7 9 October 2013
- Publications: "Collaborations with Patients Organizations" (Stefano) Nordic Life Science, review 02 2013, pag. 38



Accomplishments: Visibility - Summary

- 02/03-12-2013 EMA meeting on "risk based quality management in clinical trials with interested parties ", London
- 07/09 -10-2013 EUCROF Conference, Brussels
- 30/06 06/07 2013 Biopharmaceutical R&D and CRO Conference
- 27/28-06-2013, 6° Forum Scientifique de Pharmaco-épidémiologie,
 Paris
- 27-06-2013, Enpr-EMA meeting, London
- 18-04-2013 Pediatric WG Symposium, London (EUCROF Pediatric WG and EMA)
- 06/08-03-2013 Late Phase Research/Real-World Data, Amsterdam (EUCROF Late Phase Chair Giovanni Fiori)
- 04/06-03-2013 DIA Europe, Amsterdam, Presentation Pediatric WG



www.eucrof.eu

EUCROF/RIPPS/EMA Conference

Methodological Approaches to Overcome the Challenges of Drug Evaluation in Children

London - 18 April 2013

The EU paediatric regulation entered into force in 2007 in order to facilitate the development of medicinal products in children and to limit the extent of off-label prescriptions.

There is an apparent paradox in evaluating medicinal products in children. Clearly, clinical studies in children need to be performed in order to be able to prescribe evidence-based safe and effective medicines, however for ethical reasons, children must be protected as much as possible from the invariveness of individual procedures and from the risks of exposure of the patients involved to investigational medicinal products.

As a consequence, an ongoing consideration of these issues focuses on rendering such peedlabic studies more feasible while looking for ways to choosewent the difficulties and at the same time, respecting ethical requirements. Among these different ways, innovative methodologies for study design are of growing importance importance e.g. PK and PK PD studies using a population approach, modeling, simulation and extrapolation, adaptive dose-finding and phase III studies, use of sound and appropriate methodology for observational studies.

The aim of this conference is to establish the current level of use and PDCO recommendations for the use of innovative methodologies in the evaluation of medicinal products in children, to delineate their potential benefit and to define the conditions of their validity.

This one-day conference is aimed at professionals involved in the evaluation and development of medicinal products in children such as manufacturers, regulators, modellers, biostatisticians, investigators, co-investigators, physicians, study musses, coordinators, regulatory affairs and clinical operations personnel.



Faculty

Arm paso Alemany Pozusilo - Produkte Weiking-Group European (20 Federation (20 CMF) & FFS, Spain
Martin Chris Instau, MD, PRD - Produktion, Neckeribught, AMF) has because the Weiserig, house, finance
Martino Chris Inger-Eurone, PRD - Chair Produktion Medical Spain (20 CMF) & Medical Spain (20 CM

GREAT Post, MD, PRD. Hammerlogic, Inclusions. Inframe of United Namescology - University Parts Descript. Read United Namescology. Intro Wild Act, CEA, France. Read-Onted Namescology, Intern VM 645, CEA, France. Read-ont Committee, SAA, MC. NAWO — ARDM. Provident RIPS, France. Agents Saint Flag mood, MD — Head of Sector Human Medicines (SAA, MC.NAWO — ARDM. Act of Sanity (SAA), MX Parts Thail, PRD — Bushatistic, MJ ML B. Androson Canar Costs, MDA.

John Whitehead, PhD - Head Department Medicanetics and Brasistatics, Lescenter University, UK





Programme Committee

Amparo Memany Pozuele Pedhata Welling Greg Empero (10 Redenia o \$10 (10) 67(4), Syda Agnes Saint-Raymond, MD

Red of State Russe Medicine Systel Rose, Surgean Medicine Agory (SAM), UK. Martin of Ook linger-Exempt, PhD (Committee Chair) Ook Pedicine Welling Rose Rose on Dick Interfer (SURIE) 4,875 Honorth, German

Gérand Poes, MD, Ph.D.
Rammoch pir, Pacified des Rechons d'Orient Promoch py
Volentip Paul des certes Poet United Phomocology, Interné MARAG, GR, Fonce
Rechot: Committee, SAM, USUN WY—MSAA, Poet descripte Lineau



Organising Committee

Plangiony in Gallatti, MD - Preminde Winley Group Company (NO obtains in \$10,000). A Premilier condultative Parline Calbort, MD - Inschool: Winley Group Long and Gill Science (\$10,000). A Guide Cymre. Millos Call Ta - Productive Webspring of Words (\$10,000). (\$10,000). A This Separate Orabine Michindark, Ph.D. (Committies Chair) - Inschool: Webling Group Guegean (\$10,000). Midmain Committee Color (\$10,000).

Kont Neal - Bulgham, NPS, Renor

Jean Rangols Outlet - 1995, Roses

Al mandar Crettorich Mutanola, MD - Predicis weiting in group on BD Februius (BUBS (BUK, Spin. Michala Masoero - Archinis weiting imag Ruspon SD Rebruius (BUBS), & Hedina, hely







in pertnership with





EUCROF CONFERENCE

7-9 October 2013 Brussels, Belgium



European CRO Federation

- Stefano Marini, President (Italy).
- ✓ Dagmar Chase, Vice-president (Sermany)
- Amparo Alemany, Treasurer (Spain)
- ✓ Darina Hirdlickova, Secretary (Czech Republic)
- Christophe Golenvaux, Member (Belglum)



- Philippe Van der Hofstadt, President
- Michèle Garot, Vice President
- ✓ Julie De Wever, Secretary
- ✓ Sven Deferme, Training & Events

Programme Committee

- √ Dagmar Chase (BVMA, Germany)
- Martine Dehlinger-Kremer (BVMA, Germany)
- Izaak den Daas (ACRON, The Netherlands)
- Michèle Garot Chair (BeCRO, Belgium)
- Darlna Hrdlickova (ACRO-Cz, Czech Republic)
- ✓ Carmen Martinez (AECIC, Spain)
- Philippe Van der Hofstadt Chair (BeCRO, Beiglum)



With the contribution of Greet Musch and Kristof Bonnarens. Federal Agency for Medicines and Health Products, FAMHP

www.eucrof-conference.eu

The future of Europe in the worldwide scene of Clinical Research

The European Federation of CROs is pleased to invite you to the forthcoming European Pharmaceutical Pre-Conference and Conference that will be held in Brussels.

This event will provide a unique opportunity to listen to worldwide expert speakers from Regional and National Authorities, Pharmaceutical Industry and global CROs and will be of interest to all actors engaged in clinical research, with a primary focus on the European region.

The aim of the Pre-Conference "Clinical Outsourcing: Converting Promise to Delivery" on 7 October 2013 is to provide a balanced interactive forum for representative "stakeholders" working in clinical research and development from pharmaceutical companies and outsourcing service providers. In 3 sessions, we will share information and insight from outsourcing practices and provide direction to strategic thinking on outsourcing for the future.

The main Conference on 8-9 October 2013 will address multiple facets of this highly evolving environment, considering how clinical research is responding to the global landscape, stressing the specific challenges and strengths which characterise the three main regions being the Americas, Europe and Asia.

A series of regulations and guidances will shortly reshape the clinical research landscape in Europe. Expert speakers will provide insight in the essential features of these new frameworks. We will review how the future Clinical Trial Regulation will transform access to Clinical Trials in Europe, also hearing from National Agencies and Ethic Committees preparing for this ambitious change. Riskbased Quality Management will also be a point of focus, balancing expectations from the regulators and the perspective of Pharmaceutical Companies facing challenges on the implementation pathway.

We will critically assess how the fast changing digital technologies may offer opportunities for innovative ways of delivering Clinical Trials, considering inherent risks and challenges associated with them.

The Patient Associations will join this conference to highlight the most significant barriers to a prosperous clinical research.

Michèle Garot & Philippe Van der Hofstadt Chairs of the EUCROF Conference 2013



Accomplishments: Education

• Three free Webinars:

Darticinants

Medical Devices WG: Susanne Gerbl-Rieger CROMSOURCE

Requirements for Clinical Investigations with Medical Devices - Clarity about the actual regulatory framework - basis to understand the future

Participants.	00		
Germany:	37	Italy:	4
Belgium:	2	France:	11
Spain:	23	Sweden:	1
CZ:	3	Switzerland:	2

Ireland: 1

Ukraine:



Accomplishments: Education

• Three free Webinars:

Medical Devices WG: Judith Koehnen Theorem Clinical

EN ISO 14155:2011 - Good Clinical Practice for Medical Device Clinical Investigations

Participants:	97		
Germany:	32	Italy:	10
Belgium: Spain:	11 22	Turkey:	5
Slovakia:	3	NL: Greece:	1 5
France:	4	Poland:	1
		UK:	3



Accomplishments: Education

Three free Webinars:

Medical Devices WG: Jochen Wegerer UL MDT

Safety Reporting in Clinical Investigations with Medical Devices

Participants: 91

Germany: 35

Belgium: 3

Spain: 19 Italy: 5

Czech Republic: 16 Switzerland: 3

France: 14 NL: 7

UK: 3



Accomplishments: Communication internal

- Monthly TCs Executive Board (EB)
- Monthly TCs extended EB
- EUCROF Newsletter





Accomplishments: Communication internal

- Face-to-Face Meetings
 - DIA Vienna: 25 March 2014
 - Executive Board Meeting in Rome: 25 June 2014
 - Annual Meeting: 1 2 December 2014 in Istanbul together with SAKDER





Accomplishments: Communication external

Article for JCROA 20th anniversary (president):
 "EUCROF perspective on the present and future of CRO world development"

Meeting with ACRO und JCROA in Brussels: 7 October 2013



Accomplishments: Communication external

Visit to China (president) in 2013:

- Jinghai International Biopharma and BPO Investment Promotion Summit
 Opening Speech July 1st
- China Sourcing Summit in Hagzhou, "Clinical Trials and Outsourcing: General Trend Moving Toward East" - July 4
- International Biopharmaceutical CRO and CMO Forum in Suzhou July 5
- China (Suzhou) Service Outsourcing Development and Investing July 6





International Relations

Europe:

- Finland
- Norway
- Slovakia
- Russia
- Bulgaria
- Romania



MENA: USA: ASIA: AUSTRALIA: SOUTH AMERICA:

in progress ACRO CHINA (CROU) in progress Brazil (ABRACRO)

Japan (JCROA) Argentina



Accomplishments: Communication internal and external

- EUCROF Website
- EUCROF Brochure
- EUCROF WG leaflets







The European CRO Federation, one voice towards clinical research



EUCROF, Viale Parioli 12, 00197 Rome, ITALY www.eucrof.eu | info@eucrof.eu





Our mission is to promote Clinical Research by improving knowledge, competence, expertise and skills of Contract Research Organisations (CROs) in Europe.

Highlights

- Consists of members and associated members from 17 European countries
- Stands for 300 member CROs and over 15,000 employees.
- Represents and supports their interest towards the healthcare-related industry within the field of Clinical Research, as well as the medical and affiliated research community.
- Recognized by Regulatory Authorities as the representative for European based CROs, regularly approached to contribute to the continuous debate on the improvement of rules and regulations.

Benefits of EUCROF

- We strive to improve the collaboration and interaction amongst all stakeholders in the field of Clinical Research in Europe.
- We seek to support participation to international congresses and meetings to further underline the significant role of CROs in Clinical Research in Europe.
- We disseminate pertinent information to members.
- We organise and support training and educational programs.

How?

EUCROF's actions are carried out by Working Groups formed at the initiative of its members to develop domain-specific programmes and address corresponding issues.

- Clinical Research in Europe
 How to start a study in Europe
- Clinical Trials Legislation
- Communication
- Early Phase Clinical Study
- Education and Training
- Late Phase
- Medical Devices
- Paediatric

Member Associations



Belgium

France

Belgian Association of CROs (BeCRO) 29 members



Czech Republic

Association of CROs Czech Republic (ACRO-Cz) 15 members



Association AFORO Française des CROs (AFCROS) 60 members



Germany

Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA) 40 members



Italy

Italian Association of CROs (AICRO) 13 members



Spain

Asociación Española de Compañias de Investigación Clínica (AECIC) 32 members



Sweden

Association of CROs active in Sweden (ASCRO) 7 members



The Netherlands

Associatie van

Clinical Research Organisations in Nederland (ACRON) 40 members



Turkey

Sözlesmeli Arastirma Kuruluslari Dernegi (SAKDER) 25 members



United Kingdom

Clinical Contract Research Association (CCRA) 36 members

Associated members in Denmark, Greece, Ireland, Poland, Portugal, Switzerland and Ukraine

EUCROF aims to enforce its structuring role in the EU by encouraging and favouring the creation of national associations wherever they do not already exist.

Working Groups

- 1. Clinical Research in Europe Amparo Alemany
- 2. CROs Associations in Europe Stefano Marini
- 3. How to start a Clinical Trial in Europe Dagmar Chase
- 4. Clinical Research in Paediatrics *Martine Dehlinger-Kremer*
- 5. Clinical Trials Legislation Dagmar Chase
- Late Phase Research Giovanni Fiori

- 7. Education and Training Antoinette Van Dijk
- 8. Early Phase Research Philippe Van der Hofstadt
- 9. Medical Devices Susanne Gerbl-Rieger
- 7. Communication Christophe Golenvaux
- 8. New Technologies Yoani Matsakis



Outlook 2014 / 2015

- Various Webinars to be organised during 2014, open to the public? Paying fees?
- Meeting in San Diego with ACRO and JCROA
- Face-to-Face Meeting EB in Rome
- EUCROF Annual Meeting in Istanbul
- January 2015: 2nd EUCROF Conference in Paris celebrating EUCROF's 10th Anniversary




WG: Clinical Trials Legislation

- Detailed Guidance CT-1 (Submission to Competent Authorities, 2009)
- Detailed Guidance CT-3 (Collection, verification and presentation of Adverse Events/Adverse Reactions 2010)
- Technical Guidance List of fields for result-related information to be submitted to the 'EudraCT' clinical trials database (2010)
- Harmonised requirements for non-investigational medicinal products in CTA submissions (2010)
- Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA (2010)
- Revision of the EU Clinical Trials Directive (2009, 2011)
- FDA Guidance: A Risk-based Approach to Monitoring (2011)
- Reflection Paper: Risk-based Quality Management (2012)
- Reflection Paper: Use of IVR/IWR Systems in Clinical Trials (2012)
- Delegated Act on Post-Authorisation Efficacy Studies (2013)
- Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) (2013)
- Declaration of Helsinki (2013)



GCP IWG Reflection Paper On RBQM



Permanent Services



How to start a clinical trial in the EU/EEA



Dagmar Chase

Support to new Associations/Members/
 Associate members for their Start up



Stefano Marini & Darina Hrdlickova

Regulatory Bodies Representation



Whoever has Competence in EUCROF



Thank you **Very Much** for your attention Dziękuję bardzo za uwagę **Stefano Marini**



